Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and Yoga in Veterans at Risk for Alzheimer's Disease
NCT01811381Phase 2Unknown
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2014
- Primary completion
- Mar 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of curcumin in Mild Cognitive Impairment (MCI) and subjective cognitive impairment (SCI) (4 arms), sponsored by VA Office of Research & Development. Primary endpoint: Blood biomarkers for Mild Cognitive Impairment at 12 months. Status: unknown.
02
Drugs
curcumin
03
Conditions
Mild Cognitive Impairment (MCI)subjective cognitive impairment (SCI)
Beyond the preview
Go deeper on NCT01811381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811381.